Avascular necrosis (AVN) of the femoral head (FH) causes 5% to 12% of total hip arthroplasties (THA). It especially affects active male adults between the third and fifth decades of life. The exact worldwide incidence is unknown. There are only few data related to each country, but most of it relates to the United States.
Introduction
Avascular necrosis (AVN) of the femoral head (FH) causes 5% to 12% of total hip arthroplasties (THA). It especially affects active male adults between the third and fifth decades of life. 1 The exact worldwide incidence is unknown; there are only few data related to individual countries (e.g. Germany 5000 to 7000 patients per year). 2 Most of these data relate to the United States. 3, 4 If left untreated, AVN can lead to FH collapse and hip joint destruction. There is a 50% chance of bilateral presentation. 5 The aetiology and pathogenesis are still unclear, but a lot of risk factors have been identified through the years. Trauma, embolisation, smoking, corticosteroids, alcohol abuse, haemoglobinopathy, hyperbaric exposure, auto-immune disease, anti-tumour chemotherapy, Gaucher's disease and Caisson disease are some of the risk factors that could act individually or synergistically to produce death of bone cells.
Early presentation can be asymptomatic; when the disease becomes symptomatic the most common manifestation is deep pain in the groin referred to the buttock or knee. Physical examination may be normal until the FH collapses. The diagnosis of AVN is based on plain anteroposterior and frog-leg radiographs and MRI 8, 9 which are used for classification and staging, i.e. Ficat, 10 Steinberg 11 and Association Research Circulation Osseous (ARCO). 12 Non-surgical management has a very limited role in the treatment of AVN of the FH and only in the earliest stages.
Core decompression (CD) of the hip is the most common procedure used to treat early stages of AVN of the FH. [13] [14] [15] Due to the frequent young age of these patients, the consequences of AVN often severely impact on their leisure activities and work status. There is consequently great interest in trying to preserve the FH whenever possible. Recently, surgeons have considered combining CD with autologous bone-marrow cells, demineralised bone matrix, 16 bone morphogenetic proteins (BMPs), 17 or vascular endothelial growth factor (VEGF) to enhance bone repair in the FH.
We report a systematic review of the current medical literature on the treatment of early stage AVN of the FH using biotechnologies implanted via CD.
Materials and methods
The PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) were followed to perform this systematic review of the literature and to present the results. 18 A protocol was written stating the purpose of the review and the search strategy. A flow diagram according to PRISMA guidelines summarises our selection protocol (Fig. 1) .
Eligibility criteria
We considered as eligible for our review manuscripts that used biotechnologies associated with CD for the treatment of the AVN of the FH in the 'pre-collapse' stage. Only clinical manuscripts were selected and we included studies only on human patients aged > 18 years. Only studies in the English language were eligible for inclusion for this review. Off-topic articles, book chapters, letters to the editor, review articles, press articles, case reports, studies with less than ten participants, surgical technique articles and conference papers were excluded.
Search strategy
A systematic, computerised search for potential manuscripts was performed independently by two investigators (AC, SM). Any discrepancies were resolved by discussion. PubMed, Ovid Medline, SCOPUS and EMBASE databases were used to identify studies between January 2000 and July 2015. Keywords used for the search were: AVN or avascular necrosis or ON or osteonecrosis and core decompression; AVN or avascular necrosis or ON or osteonecrosis and stem cells; AVN or avascular necrosis or ON or osteonecrosis and bone morphogenetic proteins or BMP; AVN or avascular necrosis or ON or osteonecrosis and biotechnology; AVN or avascular necrosis or ON or osteonecrosis and scaffold; AVN or avascular necrosis or ON or osteonecrosis and autologous bone marrow between January 2000 and July 2015. The search results were reviewed for duplicates. We performed a preliminary selection of the manuscripts reading the abstracts considered relevant by title. We then analysed full-length articles in order to include them in our review. We focused our Full-text articles assessed for eligibility (n = 112)
Full-text articles excluded (n = 92)
Off-topic (32) , nonclinical studies (6) , not English language (5), book chapters (2), letters to the author (3), review articles (7), in press articles (2), case reports (13) , studies with less than 10 subjects (7), studies with human patients age <18 (4), surgical technique articles (8) , conference papers (3).
Studies included in qualitative synthesis (n = 20) attention on the references of selected articles with the aim to search other potential relevant articles. We used a summary table to collect the following data extracted from retrieved articles: study type; study design; sample size; treatment protocol; AVN classification; mean followup; and primary results.
Results

Study selection
We identified 845 abstracts using our electronic search; 733 met the initial screening inclusion criteria and the fulllength articles were retrieved and reviewed. Following the full-length reviews, 112 studies met our eligibility criteria and were retained for this review. We then selected 19 eligible reports which were included in the final analysis (Table 1) .
Core decompression (CD)
The aim of CD is to attempt to reduce intra-osseous pressure in the FH, restore vascular flow and improve pain which has been in use for over 40 years.
A current review of the literature on CD was published in 2015 by Pierce et al. 19 The ideal lesion to be treated with CD is pre-collapse and small. Standard CD procedure is typically performed by the drilling and removal of an 8-to 10-mm cylindrical core from the necrotic lesion. In an attempt to minimise complications due to the procedure, such as violation of the articular cartilage or subtrochanteric fractures, a number of surgeons started to use a small diameter pin for multiple passes through the lesion. Pierce and colleagues showed how more recent studies on CD reported better results than older studies; this could be due to a surgical improvement and a better selection of patients. 19 Yoon et al 20 in 2001 evaluated the clinical outcome of the disease when treated at different stages. After a mean follow-up of 61 months, they concluded that patients classified as Ficat stage II or III (n = 17 out of 22 hips) have an increased rate of conversion to a THA than those classified as Ficat I (n = 5 out of 17 hips). In the same study, it was shown that even the localisation of the lesion could be predictive of the outcome, particularly with better results being observed in lesions 15% smaller than the FH, located medially. Those findings were also supported by Iorio et al 21 and Mazieres et al. 22 Mont et al 23 highlighted the importance of making the diagnosis before head collapse occurred to have a significant chance to avoid a THA with CD. In a cohort of 68 hips treated post-collapse, only 29% had satisfactory outcomes.
In To treat larger lesions of the FH, surgeons have been trying to find new ways to enhance bone formation in the FH and to prevent fracture of the core tract. Non-vascularised (allograft bone or demineralised bone matrix) and vascularised bone grafts (fibula or iliac crest) have been used to try to improve the results of CD. The goal of this type of bone grafting is to decompress the osteonecrotic lesion, remove necrotic bone and provide structural support and scaffolding for repair of the subchondral bone in the FH. Vascularised grafts potentially have the advantage of re-vascularisation and promotion of osteogenesis of the FH. The non-vascularised cortical graft was originally popularised by Phemister, 27 Boettcher et al 28 and Bonfiglio et al; 29 but currently it is not commonly used. In this technique, the core tract is filled with cortical strut grafts that were harvested from either the fibular, ilium or tibia. Successful results also have been reported with vascularised fibular grafts; the hypothetical advantage of this strategy is that the vascularised bone graft provides a strut to protect the subchondral region of the FH and a scaffold for new bone repair. [30] [31] [32] However, it has not been established if the vascularised graft is the critical element in the success of this procedure. new bone. 39, 40 It is thought that MSCs implanted into the necrotic FH may differentiate into osteoblasts or vascular endothelial cells, thereby promoting bone repair and regeneration. 41 Hernigou et al 42 did a prospective study of 189 hips in 116 patients treated with autologous bone marrow grafting and CD, followed for seven years after surgery. In patients with pre-collapsed hips (University of Pennsylvania classification Stages I and II), 9/145 hips (6%) required a THA. THA was done in 25/44 hips (57%) in patients that had collapse of the FH before the CD. The authors concluded that outcomes were improved in hips that received increased numbers of progenitor cells and they believed that this technique could be used to improve repair in the area of osteonecrosis, at least in the earlier stage before mechanical failure of the FH occurs.
Bone morphogenetic proteins (BMPs)
Gangji et al 43 studied 13 patients (18 hips) with stage I or II AVN, according to the ARCO classification system. The hips were allocated to a programme of either CD (control group) or CD and implantation of autologous BMMCs (bone-marrow-graft group). After 24 months of follow-up, there was a significant reduction in pain and in joint symptoms measured with the lequesne index and the Western Ontario and McMaster universities (WOMAC) index within the bone-marrow-graft group. Five of the eight hips in the control group had deteriorated to stage III, whereas only one of the ten hips in the bone-marrowgraft group had progressed to this stage. Survival analysis showed a significant difference in the time to collapse between the two groups.
In 2010, Wang et al 44 published the results of a clinical study of 45 patients (59 hips) with stage I to IIIA AVN of the FH, according to the ARCO classification. All patients were treated using the CD technique with implantation of autologous BMMCs. The outcome was assessed by changes in Harris Hip Score (HHS), by progression in radiographic stages and by the need for a THA. The mean follow-up was 27.6 months. Pre-and post-operative evaluation showed that HHS increased from 71 to 83 points. Clinically, the overall success was 79.7% and THA was done in 7/59 hips (11.9%). Radiologically, 14 of the 59 hips exhibited FH collapse or narrowing of the coxo-femoral joint space and the overall failure rate was 23.7%. Therefore, for the authors, the autologous BMMCs implantation relieves hip pain and prevents the progression of osteonecrosis particularly in stages I to II.
Gangji et al 45 reported the results of a five-year followup of a prospective controlled study of the efficacy of bone marrow cells implantation into the necrotic lesion of the FH on clinical symptoms and the progression of AVN in comparison with CD. They studied 19 patients and 24 hips with early stage AVN (ARCO stage 1: 4 hips -ARCO stage 2: 20 hips). Visual analogue scale (VAS) was used for patient pain assessment. The severity of hip disease was gauged using lequesne algofunctional index. Symptoms of osteonecrosis were also assessed by the WOMAC score. Antero-posterior and frog-leg lateral radiographs and MRI of the affected hip were taken at the time of each clinical assessment. Radiological progression of osteonecrosis was measured by reference to ARCO-defined stages. Results of this study showed that bone marrow cell implantation afforded a significant reduction in pain and in joint symptoms and reduced the incidence of the fractural stage. At 60 months of follow-up, 8/11 hips in the control group had deteriorated to the fractural stage, whereas only 3/13 hips in the bone-marrow-graft group had progressed to that stage. Survival analysis showed a significant difference in the time to failure between the two groups. Patients had only minor side-effects after the treatments.
Sen et al 40 showed the results of a prospective randomised controlled study. The 51 osteonecrotic hips in 40 patients (ARCO stage I to II) were randomly divided into two treatment groups (A and B). Patients in group A (25 hips) were treated with CD and those in group B (26 hips) received autologous BMMCs instillation into the core tract after CD. Outcome between the two groups were compared clinically (HHS), radiographically (radiographs and MRI) and by Kaplan-Meier survival analysis after 12 and 24 months of surgical intervention. The clinical score and mean hip survival were significantly better in group B than in group A. Patients with adverse prognostic features at initial presentation (i.e. poor HHS, radiograph changes, oedema and/or effusion on MRI) had significantly better clinical outcomes and hip survival in group B than in group A.
Zhao et al 39 reported the results of a further randomised clinical study. The goal was to assess the efficacy of cultured BMSCs implantation into the FH as treatment against early stage AVN of the FH. One hundred patients (104 hips) were recruited (ARCO stages IC to IIC) and were randomly divided into a CD group alone (CD group: 50 patients, 51 hips) and a second group with FH autologous implantation of cultured BMSCs group (BMSCs group: 50 patients, 53 hips). Only two of the 53 BMSC-treated hips progressed and underwent vascularised bone grafting at five years after the operation. In the CD group, seven hips were lost to follow-up, and ten of the remaining 44 hips progressed and underwent vascularised bone grafting (five hips) or THA. BMSC treatment significantly improved the HHS as well as decreased the volume of FH of the hips pre-operatively classified as stage IC, IIB and IIC.
In 2013, lim et al 46 investigated whether multiple drilling and stem cell implantation in the treatment of AVN would improve clinical and radiographic results, compared with conventional CD and bone graft in the early stages of AVN. There were 128 patients (190 hips) who had undergone surgery were divided into two groups based on which treatment they received: a) multiple drilling and stem cell implantation (107 patients, 159 hips) or b) CD, curettage and a bone graft (21 patients, 31 hips). Indications for surgery were restricted primarily to modified Ficat stages I, IIA and IIB, although some patients with stage III disease were included if the size of the lesion was greater than 30% and if the lesion was located laterally. Among the stem cell implantation group, 21 patients (31 hips) were lost to follow-up; therefore, 86 patients (128 hips) were available for the study. The authors observed no difference in the success rate between the stem cell group and the CD group, 73/128 hips and 17/31 hips, respectively, in the Kaplan-Meier survivorship curves at the five-year follow-up. They observed statistically significant differences in the success rate between the pre-collapse state (Ficat II) and the collapsed state (Ficat III): 64/102 hips and 24/57 hips, respectively, in the Kaplan-Meier survivorship curves at the five-year followup. In the stem cell group, 59 hips were considered unsuccessful at the last follow-up, while 47 of 59 hips required additional surgery, and 12 hips had a HHS below 75 points and showed additional collapse during the follow-up period. In the CD group, 14 hips were considered unsuccessful at the last follow-up. Additional surgery has been required in 11/14 hips and three hips had a HHS below 75 points and showed additional collapse during the follow-up period.
Rastogi et al 47 performed a prospective clinical trial in 40 patients (60 hips) with stage I, II or III (ARCO system) AVN, followed up for a mean period of 24 months. The patients were allocated to two groups: a) CD and isolated mononuclear cells (group A: 30 hips) or b) CD and unprocessed bone marrow injection (group B: 30 hips). The functional outcome was assessed in terms of HHS, and disease progression was assessed radiologically by comparing the preoperative and follow-up MRI. At the two-year follow-up, there was considerable improvement in the hip function as measured by the HHS in both the groups (p = 0.031). On MRI, there was a decrease in the size of the lesion in group A. Three of 30 hips in group B required THA.
liu et al 48 showed the results of a retrospective analysis that investigated the effectiveness of CD and implantation of BMMCs with porous hydroxyapatite bone filler for the treatment AVN of the FH. Patients were eligible for inclusion in the study if they had ARCO stage I, II or IIIA AVN of the FH. There were two groups of patients in the study: a group who received CD and implantation of BMMCs (17 patients, 26 hips) and a group who received CD without implantation of BMMCs (17 patients, 27 hips). HHS was significantly increased in both groups of patients after surgery. The magnitude of increase was significantly greater in the BMMCs group as compared with the control group. VAS score was significantly decreased in both groups after surgery. The magnitude of decrease was significantly greater in the BMMCs group as compared with the control group. Radiological and clinical success rates were significantly higher in the BMMCs group as compared with the control group. Post-operative collapse of the FH was less common in the BMMCs group as compared with the control group.
Ma et al 49 conducted a prospective double-blinded randomised controlled trial to examine the effect of bonemarrow buffy coat grafting combined with CD for the treatment of AVN of the FH. The 45 patients (53 hips) with Ficat stage I to III AVN of the FH were recruited. The hips were allocated to the control group (CD + autologous bone graft) or treatment group (CD + autologous bone graft with bone-marrow buffy coat). At the 24-month follow-up, there was a significant relief in pain and clinical joint symptoms as measured by the lequesne index and WOMAC index in the treatment group. Of the hips in the control group, 33.3% deteriorated to the next stage after 24 months post procedure, whereas only 8% in the treatment group had further deterioration. The non-progression rates for stage I/II hips were 100% in the treatment group and 66.7% in the control group. Therefore, for the authors, implantation of the autologous bone marrow buffy coat grafting combined with CD is effective in preventing further progression of the early stages of AVN of the FH.
Combined techniques
Many researchers explored the combination of CD with stimulation and promotion of bone regeneration (i.e. artificial bone, autologous fibular bone, allograft fibular bone, iliac bone or osseous growth factor, and MSC-rich autologous bone marrow) to achieve better efficacy than CD alone.
In 2014, Calori et al 50 performed a retrospective clinical study to determine the efficacy of the CD technique combined with recombinant BMP-7, BMSCs and xenograft bone substitute, placed into the necrotic lesion of the FH on the clinical symptoms and on the progression of AVN. A total of 38 patients (40 hips) with early stages of AVN of the FH were studied over a four-year period. According to the Ficat classification criteria, there were seven hips with stage I osteonecrosis, 25 hips with stage II and eight hips with stage III changes. Clinical and radiographic healing occurred in 33/38 (87%) patients. In all the five failed treatments, there was a collapse of the FH with progression of the osteonecrotic lesion at the 24-month follow-up. THA was performed in these patients.
Discussion
The treatment of AVN of the FH is based on patient age, periodisation, area of osteonecrosis, position and collapse risk, and individual choice. Only by correctly mastering the therapeutic principles and adopting proper methods specifically oriented to different stages can the best therapeutic effect be achieved.
Although there are many studies concerning CD in the treatment of non-traumatic AVN of the FH, there have been inconsistencies in the reports of its clinical success (from 47% to 83%), mainly related to many different factors including: stage of AVN; skill of procedure; and duration of follow-up.
Recently, Papakostidis et al 51 performed a meta-analysis to investigate whether implantation of autologous bone marrow aspirate, containing MSCs, into the CD track would improve the clinical and radiological results of AVN of the FH compared with the classical method of CD alone. They showed that the application of autologous bone marrow concentrate (autologous cell therapy) in combination with CD is superior to CD treatment alone, as it was found to markedly decelerate the progression of the disease to the stage of FH collapse. This procedure also limited the need for THA, particularly when employed in the early (pre-collapse) stages of AVN of the FH. In this meta-analysis, the authors demonstrated that autologous cell therapy in addition to CD for the treatment of AVN of the FH resulted in reduction of painful joint symptoms and improvement in HHS compared with CD treatment alone.
However, this new therapeutic approach presents some limitations, such as the limited data on the number of cells required and the sources of MSCs that can be used (currently autologous iliac bone marrow).
CD and BMMC transplantation have shown good results in the treatment of the early stages of AVN of the FH. On the contrary, for advanced stages of AVN of the FH, the therapeutic effect of this procedure is poor and the treatment method must be selected with discretion. When the collapse has already occurred, (collapse > 4 mm and duration > 6 months) no other useful treatment can be proposed other than THA.
AVN of the FH often affects young active patients with an important negative effect on their activity and quality of life. The long-term prognosis of THA is as yet unclear. A prosthetic implantation in such patients produces important financial repercussions on the national health system also. Many cases of revision surgery will result. A treatment that can avoid or at least delay prosthetic implantation is necessary.
The most important limitation of this systematic review is the quality of the available papers. In particular, clinical studies included in our review did not provide sample, size and power calculations. Therefore, there were limited number of comparative trials and only three randomised controlled trials. We included all types of clinical studies, potentially introducing confounding and selection bias, but we felt that inclusion of these studies would provide a more comprehensive review of the literature surrounding this difficult topic. Furthermore, meta-analysis was not performed due to the limited number of comparative trials.
AVN of the FH primarily affects younger and working age individuals, thus leading to increased morbidity and functional disability in the population. Innovative treatments aimed to halt or delay progression of disease would provide a welcome alternative to those faced with progression to joint collapse and hip replacement surgery. Combining CD with biotechnologies could result in a novel long-lasting hip-preserving solution.
Current clinical studies have suggested beneficial effects on patient-reported outcomes, but definitive conclusions regarding hip survival and disease progression cannot be drawn.
This systematic review of the literature shows that there is not at present one treatment which is superior to the others in the treatment of AVN of the FH. CD alone may still have therapeutic potential, since it can stimulate bone regeneration reducing pain and improving function. Moreover, the association of biologically active substances could improve the effectiveness of CD in increasing bone healing.
These biotechnologies have demonstrated their effectiveness in the treatment of long bone nonunion and bone defects as evidenced by many studies. [52] [53] [54] [55] [56] [57] [58] Their application in cases of AVN of FH may give similar good results.
Further studies are needed to clarify the more effective biotechnologies to use in the treatment of AVN of the FH and the best combination.
Overall, considering the results of this review, the surgical treatment with CD associated with biotechnologies is advisable in early stages of AVN of the FH. In those cases in which it is not possible to save the FH, the treatment with the best outcome for the patient's quality of life remains prosthetic arthroplasty.
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